EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA

This study tests a combination of two drugs—temozolomide (chemotherapy) and atezolizumab (immunotherapy)—for people with small cell lung cancer that has spread or returned after initial treatment. The goal is to see if this combination can shrink tumors and help patients live lon…

This study tests a drug called tarlatamab in 39 people with extensive-stage small cell lung cancer, a fast-growing cancer with low survival rates. Tarlatamab works by helping the body's immune cells attack cancer cells. The main goal is to see if the drug can stop the cancer from…

This study tests whether adding the antiviral drug lamivudine to standard chemotherapy and immunotherapy can prevent small cell lung cancer from becoming resistant to treatment. About 28 adults with advanced-stage small cell lung cancer will receive the combination. The goal is t…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This study tests whether using biomarker tests to personalize maintenance therapy can help control extensive-stage small cell lung cancer. About 900 participants will receive durvalumab alone or combined with other drugs based on their cancer subtype. The goal is to see if this t…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy plus the immunotherapy drug atezolizumab. It compares the usual maintenance therapy with atezolizumab alone versus atezolizumab plus targeted radiation therapy.…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…